Kiilholma 1995.

Study characteristics
Methods	Trial design: Prospective, randomised, double‐blind, placebo‐controlled, comparative study
Participants	Participants: 88 women were randomised; 76 women were analysed. Mean age: Goserelin acetate plus HRT treatment mean 32 years (20‐48 years), goserelin acetate plus placebo treatment mean 34 years (21‐47 years) Inclusion criteria: Symptomatic patients with total pelvic symptoms score of > 3 with or without infertility Laparoscopical confirmation of endometriosis within 3 months before initiation of treatment Exclusion criteria: not stated Setting: Finland Timing: not stated
Interventions	3.6 mg SC goserelin acetate plus HRT treatment with combination of 2 mg 17β‐E2 and 1 mg norethisterone acetate (NET; Kliogest; Novo Nordisk AS, Bagsvaerd, Denmark)  (n = 43)  versus 3.6 mg SC goserelin acetate plus placebo  (n = 45)
Outcomes	Relief of overall pain: pelvic symptoms  Adverse effects Total revised AFS and total Additive Diameter of Implants scores Serum hormone levels
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: Supported by Zeneca Pharma, Helsinki, Finland. Author could not be contacted due to lack of information.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Prospective, randomized, double‐blind, placebo‐controlled, comparative study". No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, placebo‐controlled study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double‐blind, placebo‐controlled study
Incomplete outcome data (attrition bias) All outcomes	Low risk	76/88 completed study. 35/43 goserelin acetate with hormone replacement therapy and 41/45 goserelin acetate plus placebo group. Two patients discontinued the treatment because of side effects that were considered to be related to the treatment. One of them (goserelin acetate plus placebo) experienced severe depression and the other one had continuous bleeding (goserelin acetate plus HRT). Three women had pregnancy confirmed during the post‐treatment follow‐up period. Two patients underwent surgery for endometriosis, one woman started hormonal contraception, two women were treated with hormonal or IVF therapy for infertility, one patient needed hormonal therapy for a disease other than endometriosis, and one patient did not return.
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected